Clinical Trials Browser

Phase 1/2 × INDUSTRY × ripretinib × Clear all

NCT05957367 2026-03-06

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Phase 1/2 Recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05080621 2022-01-05

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Phase 1/2 Withdrawn

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors